Literature DB >> 34059749

Role of cytoplasmic localization of maspin in promoting cell invasion in breast cancer with aggressive phenotype.

Tomohiko Sakabe1, Makoto Wakahara2, Goshi Shiota3, Yoshihisa Umekita4.   

Abstract

Mammary serine protease inhibitor (maspin) is a tumor suppressor gene that is downregulated during carcinogenesis and breast cancer progression. While the nuclear localization of maspin is essential for tumor suppression, we previously reported that the cytoplasmic localization of maspin was significantly correlated with poor prognosis in breast cancer patients. To understand the mechanisms that underlie oncogenic role of cytoplasmic maspin, we studied its biological function in breast cancer cell lines. Subcellular localization of maspin in MDA-MB-231 breast cancer cells was mainly detected in the cytoplasm, whereas in MCF10A mammary epithelial cells, maspin was present in both cytoplasm and nucleus. In MDA-MB-231 cells, maspin overexpression promoted cell proliferation and cell invasion, whereas maspin downregulation resulted in the opposite effect. Further, we observed that SRGN protein levels were increased in MDA-MB-231 cells stably overexpressing maspin. Finally, maspin overexpression in MDA-MB-231 cells resulted in the N-cadherin and epithelial mesenchymal transition (EMT)-related transcription factors upregulation, and TGFβ signaling pathway activation. These results suggested that cytoplasmic maspin enhances the invasive and metastatic potential in breast cancer cells with aggressive phenotype by inducing EMT via SRGN/TGFβ axis. This study demonstrated a novel biological function of cytoplasmic maspin in progression of breast cancer cells with an aggressive phenotype.

Entities:  

Year:  2021        PMID: 34059749     DOI: 10.1038/s41598-021-90887-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  37 in total

1.  Triple-negative breast cancer: clinical features and patterns of recurrence.

Authors:  Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition.

Authors:  Khatri Latha; Weiguo Zhang; Nathalie Cella; Heidi Y Shi; Ming Zhang
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

3.  Maspin suppresses survival of lung cancer cells through modulation of Akt pathway.

Authors:  Eunsook Nam; Chaehwa Park
Journal:  Cancer Res Treat       Date:  2010-03-31       Impact factor: 4.679

4.  Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells.

Authors:  S Sheng; J Carey; E A Seftor; L Dias; M J Hendrix; R Sager
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model.

Authors:  H Y Shi; W Zhang; R Liang; S Abraham; F S Kittrell; D Medina; M Zhang
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

6.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Authors:  G Curigliano; H J Burstein; E P Winer; M Gnant; P Dubsky; S Loibl; M Colleoni; M M Regan; M Piccart-Gebhart; H-J Senn; B Thürlimann; F André; J Baselga; J Bergh; H Bonnefoi; S Y Brucker; F Cardoso; L Carey; E Ciruelos; J Cuzick; C Denkert; A Di Leo; B Ejlertsen; P Francis; V Galimberti; J Garber; B Gulluoglu; P Goodwin; N Harbeck; D F Hayes; C-S Huang; J Huober; K Hussein; J Jassem; Z Jiang; P Karlsson; M Morrow; R Orecchia; K C Osborne; O Pagani; A H Partridge; K Pritchard; J Ro; E J T Rutgers; F Sedlmayer; V Semiglazov; Z Shao; I Smith; M Toi; A Tutt; G Viale; T Watanabe; T J Whelan; B Xu
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

Review 7.  Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Authors:  Carsten Denkert; Cornelia Liedtke; Andrew Tutt; Gunter von Minckwitz
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

8.  The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy.

Authors:  Berta Ben Shachar; Orit Feldstein; Dalia Hacohen; Doron Ginsberg
Journal:  Mol Cancer Res       Date:  2010-03-02       Impact factor: 5.852

9.  A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene.

Authors:  S S Schneider; C Schick; K E Fish; E Miller; J C Pena; S D Treter; S M Hui; G A Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

10.  Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions.

Authors:  Shirley L Smith; Suzanne G Watson; Daniel Ratschiller; Mathias Gugger; Daniel C Betticher; Jim Heighway
Journal:  Oncogene       Date:  2003-11-27       Impact factor: 9.867

View more
  1 in total

1.  Investigation of the Subcellular Localization-Dependent Anti- or Pro-Tumor Functions of Maspin in Human Lung Adenocarcinoma Cell Line.

Authors:  Takahiro Matsushige; Tomohiko Sakabe; Yoshihisa Umekita
Journal:  Yonago Acta Med       Date:  2022-01-04       Impact factor: 1.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.